



AREA DRUG & THERAPEUTICS COMMITTEE

ANNUAL REPORT

APRIL 2020 – MARCH 2021

CONTENTS

Introduction	Page 3
Remit	Page 3
Structure and organisation	Page 4
ADTC Membership	Page 4
Applications for Approval	Page 5
Schedule of Business April 2020 – March 2021	Page 5 - 6
Attendance of Members	Page 7

Introduction:


The Area Drug and Therapeutics Committee is a standing committee of NHS Borders Board. Patient Safety is at the heart of all considerations and decisions made by the ADTC and its sub-committees.

Remit

1. To advise and support the strategic direction of all aspects of medicines governance and usage in all care settings ensuring inclusion within wider strategic planning carried out by the NHS Board.
2. To ensure multi-stakeholder engagement and joint working on all medicine related issues within all care settings, including social care settings.
3. To develop and monitor Borders-wide prescribing policies and treatment guidelines to optimise safe and cost effective use of medicines.
4. To advise, monitor and co-ordinate the development and approval of policies and procedures relating to prescribing, administration and the safe and secure handling of medicines and support NHS Borders Board in meeting its statutory responsibilities in relation to medicines and prescribing.
5. To support NHS Borders Board in the delivery of a comprehensive approach to national policy regarding medicines, linking with Regional and National groups.
6. To oversee the systems for safer medicines use, including SPSP Safer Medicines Group / Medicines Reconciliation
7. To respond to national directives and initiatives related to the use of medicines, in particular that issued by the Scottish Medicines Consortium, Scottish Intercollegiate Guidelines Network (SIGN), National Institute for Healthcare and Clinical Excellence (NICE),.
8. To oversee the system for evaluation of new therapeutic developments and effectively manage their introduction into routine use in NHS Borders. The committee will consider new medicine applications where a decision is required before the next Formulary Committee meeting.
9. To ensure systems are in place for the dissemination of information and advice to professional staff, patients and public promoting safe, efficient and cost-effective use of medicines taking into account current evidence and best practice.
10. To promote seamless care for patients transferring between community and hospital care.
11. To ensure equitable access to medicines through non-medical prescribing and patient group directions.
12. The ADTC provides advice to NHS Borders, and supports the work of the Area Medical Committee, Area Pharmaceutical Committee, Area Nursing and Midwifery Committee and other relevant profession committees.

Structure and Organisation:

Standing sub committees/groups reporting to the Area Drug and Therapeutics Committee (ADTC) are:-



Minutes from recent meetings of these groups are included in the ADTC agenda. The full ADTC meets on alternative months with the Borders Formulary Committee.

ADTC MEMBERSHIP: 2020/21 – NHS BORDERS

Alison Wilson, Chair (Non-executive Board Member; Chair of Area Clinical Forum)

Dr Edward James, Consultant Microbiologist

Dr Gemma Alcorn, Consultant Physician DME, BGH – until September 2020

Dr Effie Dearden, Consultant Physician DME, BGH – from January 2021

Cathryn Park, Lead Pharmacist Acute Care & Medicines Governance / Deputy Director of Pharmacy

Keith Allan, Vice Chair – Public Health Consultant

Dr Elliot Longworth, General Practitioner, West Linton Medical Practice

Dr Nicola Henderson, General Practitioner, Coldstream Medical Practice

Liz Leitch, Formulary Pharmacist

Keith Maclure, Senior Pharmacist medicines utilisation and planning

Adrian Mackenzie, Lead Pharmacist – Community Pharmacy

Mark Clark, Lead Nurse Non-Medical Prescribing and Medicines Governance – until July 2020

Rhona Morrison, Lead Nurse Non-Medical Prescribing and Medicines Governance – from September 2020

Andrew Leitch, Lay member (nominated by the Patient & Public Forum)

Kate Warner, Committee Secretariat (PA to Director of Pharmacy)

Applications for Approval April 2020 – March 2021

NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 13 TH MAY 2020			
NMA	Indication	Speciality	ADTC Decision
No New Medicines Applications at this meeting			
NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 8 TH JULY 2020			
NMA	Indication	Speciality	ADTC Decision
LAT Gel	Topical use in anaesthetisation for paediatric in Emergency Department	ED	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 16 TH SEPTEMBER 2020			
NMA	Indication	Speciality	ADTC Decision
Amantadine	Fatigue in multiple sclerosis	Neurology	Category C
NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 18 TH NOVEMBER 2020			
NMA	Indication	Speciality	ADTC Decision
No New Medicines Applications at this meeting			
NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 20 TH JANUARY 2021			
NMA	Indication	Speciality	ADTC Decision
No New Medicines Applications at this meeting			
NEW MEDICINE APPLICATIONS BROUGHT TO ADTC MEETING OF 24 TH MARCH 2021			
NMA	Indication	Speciality	ADTC Decision
Meeting cancelled – no New Medicines Applications			

Schedule of business considered – April 2020 – March 2021

Meeting	Title of Business Discussed
13.05.2020	Matters Arising: None
	New Medicines Applications: None
	Non Formulary Requests: None
	Patient & Medicine Safety: None
	Clinical Policies, Procedures and Guidelines: Medicines Governance during Covid19; Disease Modifying Anti-Rheumatic Drugs; Health Equality report for Homecare Policy; General dental practice remote prescribing process.
	For Information and Noting: Covid19 process change tracker; Anti-coagulation advice from Warfarin to a DOAC during Covid19 pandemic; Anticoagulation bridging for patients with severe renal impairment or end stage renal disease; information for clinicians managing covid19 patients – thromboprophylaxis, VTE and DIC and blood product support; Guidance and pathway for end of life care patients; guidance for intravenous fluid and electrolyte prescription in adults – changes to potassium chloride IV monograph. No minute available from sub committees.
	AOCB: None
Meeting	Title of Business Discussed
08.07.2020	Matters Arising: None
	Presentation: Recovery & Remobilisation following Covid19 Pandemic – from Director of Workforce
	New Medicines Applications: LAT Gel
	Non Formulary Requests: Prucalopride
	Patient & Medicine Safety: None
	Clinical Policies, Procedures and Guidelines: Guidance for GP practices and Care Homes regarding the supply and administration of anticipatory care medicines during Covid19; Medicines Resource Group TOR.
	For Information and Noting: Vancomycin prescribing; Management of Vitamin D insufficiency/deficiency in mental health inpatients; VTE Prophylaxis with Apixaban; Medication Algorithm secondary prevention after TIA Ischaemic Stroke; Covid19 process change tracker; HEPMA update; Guidance for Dexamethasone – Covid19. Minute from Borders Formulary Committee and NHS Lothian ADTC meetings.
AOCB: New SMC process; ADTC Annual Report; Dexamethasone and Remdesivir.	
Meeting	Title of Business Discussed

16.09.2020	Matters Arising: None
	New Medicines Applications: Amantadine
	Non Formulary Requests: Sativex.
	Patient & Medicine Safety: Datix review.
	Clinical Policies, Procedures and Guidelines: Kiovig protocol for IV infusion to be removed; ADTC TOR; Pharmacy Annual Report.
	For Information and Noting: closure of EAMS Remdesivir; PACS T2 decision spreadsheet; cystic fibrosis medicines; SMC ultra-orphan validation process – medicines. Minute from Borders Formulary Committee, Antimicrobial Team, Anticoagulant Committee; IV Therapy Group and NHS Lothian ADTC meetings.
	AOCB: Sativex applications; request for PACS Tier2 national review panel representation.
Meeting	Title of Business Discussed
18.11.2020	Matters Arising: None
	New Medicines Applications: None
	Non Formulary Requests: None
	Patient & Medicine Safety: Datix review.
	Clinical Policies, Procedures and Guidelines: Physical Health Monitoring for patients prescribed antipsychotics and mood stabilisers; Independent/Nurse Formulary Prescriber (NMP) Policy update; SOP for Healthcare Support Workers – Controlled Drugs; Prescribing of non-SMC-approved drugs through PACS T2; East Regional Formulary; Pharmacy First Formulary update.
	For Information and Noting: Repurposing Medicines Guidance – Care Homes and Hospices during Covid19 pandemic; Cabinet Secretary for Health & Sport response letter; Naloxone Supply Framework; Sign 160 Guidance – Management of suspected bacterial lower UTI in adult women; Yellow Care Annual Report 2019-20; NFR form update; HIS guidance link – patient consent SACT; minutes from Borders Formulary Committee, Antimicrobial Team, IV Therapy Group and NHS Lothian ADTC meetings.
AOCB: PGD approval emails; welcome to new member Dr Effie Dearden.	
Meeting	Title of Business Discussed
20.01.2021	Matters Arising: Update to Independent/Nurse Formulary Prescriber (NMP) Policy; Guanfacine SCA.
	New Medicines Applications: REMAP-CAP trial
	Non Formulary Requests: Levocartine
	Patient & Medicine Safety: Datix review.
	Clinical Policies, Procedures and Guidelines: Drug & Therapeutic Industry Engagement Policy and Summary; SOP for Prescribing Pads distribution.
	For Information and Noting: Ward Automated Cabinet update; HEPMA update; Therapeutic anticoagulation (Heparin) in the management of severe Covid19 patients; letter from CPO - Astra Zeneca vial doses; Tocilizumab and Sarilumab for ICU patients with Covid19 pneumonia; Lothian formulary website; minutes from Borders Formulary Committee, IV Therapy Group, Wound Formulary Group and NHS Lothian ADTC meetings.
AOCB: Change to ADTC meeting date.	
Meeting	Title of Business Discussed
24.03.2021 Meeting Cancelled Approvals by email	Matters Arising: None
	New Medicines Applications: None
	Non Formulary Requests: None
	Clinical Policies, Procedures and Guidelines: Items for approval sent by email: update to Homecare Medicines Services Policy; Scot CAP Colon Capsule Endoscopy
	For Information and Noting: East Regional Formulary update; Outcomes of recovery and principle trials; anticoagulation bridging for patients with severe renal impairment or end stage renal disease; minutes from Borders Formulary Committee, Anticoagulant Committee; and NHS Lothian ADTC meetings.
	AOCB: None

Attendance for ADTC during 2020/21

Dates of Meetings						
	13.05.20 by email	08.07.20	16.09.20	18.11.20	20.01.21	24.03.21
Name						
Alison Wilson	✓	✓	✓	✓	✓	CANCELLED DUE TO APOLOGIES
Dr Edward James	✓	-	-	✓	-	
Dr Gemma Alcorn	✓	-	-	-	-	
Dr Effie Dearden	-	-	-	-	✓	
Dr Nicola Henderson	✓	-	-	✓	✓	
Dr Elliot Longworth	✓	✓	✓	-	-	
Keith Allan	✓	✓	-	✓	✓	
Cathryn Park	✓	✓	✓	✓	-	
Liz Leitch	✓	✓	✓	✓	-	
Keith Maclure	✓	✓	✓	✓	✓	
Adrian Mackenzie	✓	✓	✓	✓	✓	
Mark Clark	✓	-	-	-	-	
Rhona Morrison	-	-	✓	-	✓	
Andrew Leitch	✓	-	-	-	✓	
Kate Warner (Minute)	✓	✓	✓	✓	✓	
Invited Guests:						
Andy Carter		✓				
Rebecca Edden		✓				
Dr Paul Neary				✓		
Jane Browning				✓		
Kirsty MacFarlane				✓		
Dr Joanna Bredski				✓		
Kirsty Douglas				✓		
Dr Charlotte Squires				✓		
Dr Michael McDermott				✓		

There were no declarations of interest at ADTC meetings during 2020/21.